Verseon Corporation announced that it has submitted a phase I clinical trial protocol for VE-1902, its lead PROAC (precision oral anticoagulant), to the Bellberry Human Research Ethics Committee (HREC) in Australia. The proposed study is a double-blinded, randomized, placebo-controlled phase I trial to assess the safety and tolerability of VE-1902 tablets in healthy volunteers with once-a-day oral dosing. The phase I trial is expected to start in Third Quarter 2018, after approval by the HREC and acknowledgment by the Therapeutic Goods Administration. VE-1902 is the first clinical candidate from Verseon's novel class of PROACs, which have shown good efficacy in multiple preclinical studies but do not disrupt platelet function. This unique feature could explain the low bleeding risk of these precision anticoagulants and may allow PROACs to become the first oral anticoagulants suitable for long-term anticoagulant-antiplatelet combination therapy.